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Abstract 
Background: Despite few studies, a monitoring of a neuromuscular blockade with a train of four (TOF) is recom‑
mended in intensive care unit (ICU). Our objective was to compare the results of ulnar and facial TOF measurements 
with an overall clinical assessment for neuromuscular blockade in ICU patients treated with recommended doses of 
atracurium or cisatracurium, including patients with acute respiratory disease syndrome (ARDS).
Methods: We prospectively included in two ICUs 119 patients, 94 with ARDS, who required a neuromuscular 
blockade for more than 24 h. Three levels of neuromuscular blockade were defined: “over‑paralyzed” (TOF = 0), “well‑
paralyzed” (TOF = 1–2), and “under‑paralyzed” (TOF = 3–4). Physicians blinded for TOF counts were asked to classify 
patients clinically as “over‑paralyzed,” “well‑paralyzed,” or “under‑paralyzed”. Patients were assessed two times daily.
Results: For the whole population 996 ulnar and facial TOF measurements and clinical assessments were obtained 
(846 with cisatracurium and 150 with atracurium). Proportions of patients classified as over‑paralyzed, well‑paralyzed, 
and under‑paralyzed based on TOF measurements and clinical assessments differed significantly (p < 0.0001). The 
number of observed agreements between clinical assessments and facial TOF measurements was of 19.08% (κ = 0.06) 
and of 17.37% with ulnar TOF measurements (κ = 0.04), while it was of 62.75% between ulnar and facial TOF measure‑
ments (κ = 0.45). Results were similar for cisatracurium and atracurium. Repeated facial TOF measurements performed 
on the first 4 days of mechanical ventilation in ARDS patients showed that the proportion of patients TOF = 1–2 was 
around 8% and did not vary significantly with time (p = 0.9), proportion of patients TOF = 3–4 increased from 24 to 
40% (p = 0.01), proportion of patients TOF = 0 decreased from 71 to 53% (p = 0.005) while objectives for protec‑
tive ventilation were achieved. Proportions of facial and ulnar TOF = 0 were significantly higher among patients with 
ICU‑acquired weakness (ICU‑AW) versus those who did not develop ICU‑AW (51 vs. 40%, p = 0.03, and 76 vs. 62%, 
p = 0.006, respectively).
Conclusions: The study provides data on clinical and TOF monitoring of neuromuscular blockade, which are widely 
divergent in ICU patients receiving recommended doses of benzylisoquinoliniums.
Keywords: Intensive care unit, Muscular weakness, Neuromuscular blockade, Train‑of‑four monitoring, 
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Background
Neuromuscular blocking agents (NMBAs) are often 
used in association with adequate analgesia and sedation 
for the following conditions: management and facilita-
tion of mechanical ventilation (MV), management of 
elevated intracranial or intraabdominal pressure, treat-
ment of muscle spasms, and reduction in oxygen con-
sumption [1, 2]. Recently, NMBAs became common 
intravenous medications used within the intensive care 
unit (ICU) since Papazian et al. [3] enhanced the role of 
NMBAs when they found a beneficial effect of a neuro-
muscular blockade on the mortality in acute respiratory 
distress syndrome (ARDS). The previous recommenda-
tions of the American and French critical care societies 
for sustained neuromuscular blockade are of C grade for 
indications and of B grade for monitoring [2, 4]. In the 
clinical practice guidelines for sustained neuromuscular 
blockade in the adult critically ill patient published in 
2016 [5], NMBAs are suggested in ARDS patients with a 
ratio PaO2/FiO2 less than 150 (weak recommendation) 
but no dosage is mentioned. All these recommenda-
tions [2, 4, 5] suggest that in ICU patients the appropri-
ate depth of neuromuscular block may be variable and 
depends on the reason for neuromuscular blockade, the 
expected patient outcome, and the phase of the disease. 
Monitoring the depth of a neuromuscular blockade with 
peripheral nerve stimulation (PNS) is recommended only 
in combination with a clinical assessment by critical care 
societies [2, 4, 5]. The most commonly used tool is the 
train of four (TOF), and previous recommendations sug-
gest dosing titration of NMBAs to one or two visualized 
muscle twitches [2, 4]. Of note, in the study of Papazian 
et  al. [3], PNS was not permitted and in the 2016 prac-
tice guidelines [5] no TOF objective is recommended. 
North American surveys performed in the 2000s 
reported that 84–91% of physicians used PNS for moni-
toring but also that neuromuscular blockade practices 
varied greatly between intensive care units (ICUs) [6, 7]. 
Using TOF monitoring in the ICU may result in a reduc-
tion of NMBAs’ dose and a subsequent decrease risk of 
complications related to prolonged and/or excessive 
blockade, such as intensive care unit-acquired weakness 
(ICU-AW) [8, 9]. The benefits and limitations of TOF 
stimulation were primarily determined from studies per-
formed in operative room patients [10, 11], with results 
that may not be generalizable to ICU patients. In criti-
cally ill patients, the duration of neuromuscular block-
ade is longer, sepsis and/or shock is often present, and 
pharmacokinetic is difficult to predict [12–14]. Lastly, 
agreement between subjective and objective means of 
assessing the degree of neuromuscular blockade has been 
little studied in ICU [15–17]. Thus, we designed a pro-
spective observational study in two ICUs using NMBAs 
with infusion rates following recommendations with the 
aims (1) to describe and compare TOF measurements 
obtained at ulnar and facial sites with clinical evaluation 
of depth blockade, (2) to focus on the results obtained 
in ARDS patients with time analysis, and (3) to evaluate 




The study was conducted between April 1, 2014, and 
March 31, 2015, in two different ICUs: in a 21-bed medi-
cal ICU in Rennes University Hospital (center 1) and in 
a 14-bed mixed medical-surgical ICU in Saint-Brieuc 
General Hospital (center 2). The study was approved by 
the Rennes University Hospital’s ethic committee (No. 
14-17), and no informed consent was required because of 
the observational nature of the study. A non-opposition 
form was provided to families.
All patients aged over 18 years with a planned duration 
of a neuromuscular blockade for more than 24  h were 
screened, and those treated at least 24  h with NMBAs 
were finally included for analysis. Exclusion criteria were 
contraindications to NMBAs (malignant hyperthermia, 
history of anaphylaxis with NMBAs), the inability to 
assess muscle strength or TOF count (neuromuscular 
disease, admission for cardiac arrest, body core tempera-
ture below 36.5 °C), pregnancy, moribund state, decision 
to withhold life-sustaining treatment, refusal of the fam-
ily, and continuous infusion of NMBAs for more than 
12 h before screening.
Neuromuscular blockade
Before neuromuscular blockade, sedatives and opioids 
were titrated by nurses according to the Ramsay Sedation 
Scale in center 1 [18] with an objective of 6 and the Rich-
mond Agitation Sedation Scale in center 2 [19] with an 
objective of −5. There was no daily sedation interruption. 
Sedatives used were midazolam or propofol, and opioids 
used were sufentanil or morphine. The NMBAs used 
were benzylisoquinoliniums: cisatracurium in center 1 
and atracurium in center 2. Boluses and initial infusion 
rates followed the 2002 and 2008 recommendations using 
patient’s body weight on admission: 0.15  ±  0.05 and 
0.5 ± 0.2 mg kg−1 h−1 for cisatracurium and atracurium, 
respectively [2, 4]. The management of the neuromuscu-
lar blockade was left to the physician in charge, who was 
blinded about results of the TOF, according to its clini-
cal evaluation. Total doses, durations of treatment, and 
NMBAs’ infusion rates were recorded daily.
The PNS used were TOF-Watch-S® (Organon Ltd., Dub-
lin, Ireland) in center 1, and Innervator® (Fisher-Paykel 
Health Care, Baxter, Maurepas, France) in center 2. The TOF 
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delivers 4 supramaximal electrical impulses that involve four 
equally strong twitches of the stimulated muscle. A fade of 
the twitches appears when the neuromuscular blockade 
increases [10, 11]. To homogenize practices, both neuromus-
cular monitors were used in the same way, without accelero-
myography: the intensity of the stimulating current was set 
at 50  mA, and the TOF count was visually assessed. After 
cleaning the skin, monitoring of the neuromuscular block-
ade was performed using surface electrodes (Red Dot®, 3M 
Health Care, Neuss, Germany) on the temporal branch of the 
facial nerve and on the ulnar nerve at the wrist, with assess-
ment of twitches of the orbicularis oculi and adductor polli-
cis muscles, respectively [20, 21]. The presence or absence of 
edema was noted before each measurement. Electrodes were 
changed at least once per day. Monitoring was performed 
twice a day by one of the investigators. At each assessment, 
we asked the senior physician in charge, blinded about 
results of the TOF, to evaluate comprehensively the depth 
of muscle relaxation as “over-paralyzed,” “well-paralyzed,” or 
“under-paralyzed.” In both ICUs, the clinical assessment was 
based on the attentive observation of patient’s movements, 
ventilator asynchronies, respiratory pressures, and presence 
of cough or not [22]. Measurements of the TOF on the ulnar 
nerve were performed arbitrary 4 h after the end of the infu-
sion of the NMBAs, that is beyond five elimination half-lives, 
to record residual paralysis, and patients with TOF < 4 were 
reassessed at 8 h.
Data collection
The following variables were recorded: age, gender, body 
mass index, Simplified Acute Physiologic Score II [23], 
and Sequential Organ Failure Assessment the day of 
NMBA initiation [24]. In addition, comorbidities, which 
could affect the pharmacokinetics of NMBAs or risk of 
ICU-AW, were noted: diabetes mellitus, cirrhosis, renal 
disease, corticosteroid treatment [1, 25]. We also noted 
the reasons for ICU admission and neuromuscular block-
ade, total doses, and duration of hypnotics and opioids.
All ARDS patients received protective ventilation and 
were ventilated as follows: assist-control mode, initial tidal 
volume targeted at 6 mL per kilogram of predicted body 
weight, positive end-expiratory pressure (PEEP) level was 
selected from the PEEP-FiO2 table proposed by the ARDS 
network [26], and end-inspiratory pressure was measured 
to be kept below 30 cm of water. Therefore, we recorded 
the major components of these parameters at the time of 
each measurement, i.e., the plateau pressure, the calcu-
lated driving pressure, and the ratio of the partial pres-
sure of arterial oxygen (PaO2) to the fraction of inspired 
oxygen (FiO2). Of the treatments received, we noted the 
duration of catecholamines and use of renal replacement 
therapy. Duration of MV, duration of ICU and hospital 
stay, ICU and hospital mortality were finally recorded.
Muscle strength was evaluated with the use of the 
Medical Research Council (MRC) scale, 7  days after 
awakening the patient, as previously described [27]. This 
scale assesses six muscle groups, with a score for each 
group from 0 (paralysis) to 5 (normal strength). ICU-AW 
was defined by an overall score of less than 48/60 [27].
Definitions and endpoints
Based on 2002 and 2008 recommendations [2, 4], three 
levels of neuromuscular blockade were determined: 
“over-paralyzed” defined by a TOF  =  0/4, “well-para-
lyzed” defined by a TOF = 1–2/4, and “under-paralyzed” 
defined by a TOF  =  3–4/4. At each measurement, the 
patient was classified in one of the three categories for 
the facial and the ulnar sites. Regarding clinical assess-
ment, physicians were asked to judge the adequacy of 
the muscle relaxation, taking into account the clinical 
context. Consequently in some cases depth of neuromus-
cular blockade could be considered as excessive by some 
physicians.
The primary endpoint was to compare the propor-
tions of patients classified as “over-paralyzed,” “well-
paralyzed,” or “under-paralyzed” between the ulnar and 
facial TOF and physicians’ clinical assessment and to 
assess agreements between measurements. The second-
ary endpoints included an analysis of trends in the TOF 
values over time and comparisons of recorded plateau 
pressures, calculated driving pressures, and PaO2/FiO2 
ratios according to the facial TOF levels in the subgroup 
of ARDS patients. The third endpoint was to determine 
whether results for TOF measurements were associated 
with ICU-AW.
Statistical analysis
Continuous variables were expressed as medians and 
interquartile ranges and were compared using a non-
parametric Mann–Whitney U test or a Kruskal–Wallis 
test. Categorical variables were expressed as numbers 
and percentages and were compared using a Chi-square 
test or a Fisher exact test and a Chi-square test for trends 
when required. The tests were two-sided, and we consid-
ered a p value of less than 0.05 to be statistically signifi-
cant. Treating the levels of neuromuscular blockade as 
categorical, a kappa statistic was calculated to analyze the 
agreement between the facial TOF measurements, the 
ulnar TOF measurements, and the clinical assessments. 
Statistical analyses were performed using MedCalc, ver-
sion 11.3.3.0 (MedCalc Software, Mariakerke, Belgium).
Results
Patients’ characteristics
During the study period, 254 patients who received 
NMBAs were screened for the study. Of these patients, 
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134 could not be included. One of the 120 patients 
included was finally excluded because of a chronic neu-
rological disease unknown at the time of inclusion 
(Fig.  1). Of the 119 patients included in the study, 97 
(82%) patients were hospitalized in center 1 and 22 (18%) 
in center 2. The main characteristics of the patients are 
shown and distinguished according to the inclusion 
center in Table 1. The main reason for the neuromuscu-
lar blockade was ARDS. Patients differed significantly 
between the two centers for main reason for ICU admis-
sion and neuromuscular blockade. Of note, all patients in 
center 1 received cisatracurium and all patients in center 
2 received atracurium.
For the whole population, the duration of invasive MV 
was 11  days [7–24]; the length of stay in the ICU was 
14 days [8–26]; and the length of stay in the hospital was 
27  days [15–56]. Forty-seven (39%) patients died in the 
ICU, and 6 (5%) additional patients died in the hospital. 
ICU mortality rates did not differ between centers after 
comparison (p = 0.15).
Neuromuscular blockade
At inclusion, the NMBA infusion rates were 
0.18  mg  kg−1  h−1 [0.16–0.22] for cisatracurium and 
0.52  mg  kg−1  h−1 [0.47–0.63] for atracurium. For the 
whole population, the median duration of the NMBA 
infusion was 67 h [38–121], without differences between 
the two centers (64 h [38–124] for center 1 vs. 85 h [40–
118] for center 2, p  =  0.37). At the end of the NMBA 
infusion, the ulnar TOF was performed in all the assess-
able patients (n = 98). Six (6%) had TOF < 4 at 4 h. Of 
them, 4 could be reassessed at 8 h, and they all had a TOF 
of 4/4.
Comparisons between TOF measurements and clinical 
assessments
On the whole population 996 TOF facial and ulnar meas-
urements and 996 clinical assessments were performed, 
846 groups of measurements in patients receiving cisa-
tracurium (center 1) and 150 groups of measurements in 
patients receiving atracurium (center 2).
On the whole population proportions of patients clas-
sified as “over-paralyzed,” “well-paralyzed,” or “under-
paralyzed” differed significantly when results for clinical 
assessments were compared with results obtained with 
facial and ulnar TOF measurements (Fig.  2). Based on 
clinical assessment patients were considered to have 
adequate muscle relaxation nearly 9 out of 10 times while 
only 1 patient out of 10 was considered well-paralyzed 
according to TOF measurements. Statistical results were 
similar whether comparisons were performed on the 
whole population or in subgroups of patients receiving 
cisatracurium or atracurium (Additional file 1: Table S1).
When compared, results obtained with facial and ulnar 
TOF measurements differed significantly. Compared 
to results obtained at ulnar site, patients were classified 
twice as often under-paralyzed based on results obtained 
at facial site.
Of note, edema did not modify TOF values since there 
was no difference in patients with edema compared to 
patients without edema (data not shown).
Agreement between TOF measurements and clinical 
assessments
Based on kappa statistic, we found similar levels of agree-
ment for comparisons between TOF measurements and 
clinical assessments in center 1 and center 2 (Additional 
file 2: Tables S2a–S2i). When the whole population was 
considered, the number of observed agreements was 190 
(19.08%) (κ  =  0.06) between clinical assessments and 
facial TOF measurements and of 173 (17.37%) (κ = 0.04) 
between clinical assessments and ulnar TOF measure-
ments. The level of agreement was slightly higher for 
comparison between facial und ulnar measurements 
since the number of observed agreements was of 625 
(62.75%) (κ = 0.45).
Subgroup analysis on ARDS patients
We analyzed data recorded on the first 4  days of MV 
for time analysis. Results for clinical assessments did 
not vary significantly with time. Based on ulnar and 
facial TOF measurements, from day 0 to day 3 of MV 
the proportion of patients considered “well-paralyzed” 
did not vary significantly while the proportion of 
1810 patients were hospitalized 
during the study period
1556 without neuromuscular blockade
254 with neuromuscular blockade
120 were included
134 were not included
65 cardiac arrests
19 moribund patients
16 duration of neuromuscular blockade < 24h
12 neuromuscular diseases




94 acute respiratory distress syndromes
7 exacerbations of chronic obstructive 
pulmonary disease
3 status asthmaticus
6 others respiratory failures
5 abdominal compartment syndromes
4 cardiogenic shocks
1 was excluded because of a neuromuscular 
disease unknown at the inclusion
Fig. 1 Flowchart of patients
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patients “under-paralyzed” increased significantly. The 
proportion of patients “over-paralyzed” decreased sig-
nificantly with time according to facial TOF measure-
ments and tended to decrease significantly according 
to ulnar measurements (Fig.  3). Similar results were 
found whether patients received cisatracurium or atra-
curium (Additional file  3: Table S3). When PaO2/FiO2 
ratios, plateau pressures, and calculated driving pres-
sures were compared daily between the three different 
levels of neuromuscular blockade defined by the facial 
measurements of the TOF on the first 4  days of MV, 
no significant difference was found (Table 2). The daily 
dose of cisatracurium used in center 1 increased from 
150  mg (90–240, day 0) to 300  mg (166–330, day 3) 
(p < 0.01 after comparison), and the daily dose of atra-
curium used in center 2 increased from 219  mg (153–
235, day 0) to 362 mg (217–454, day 3) (p = 0.03 after 
comparison).
Table 1 Patients’ characteristics at the inclusion
Continuous variables are reported as medians and interquartile ranges (25th–75th percentiles), and categorical variables as numbers and percentages
SAPS II Simplified Acute Physiologic Score II, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, ARDS acute respiratory distress syndrome, COPD 
chronic obstructive pulmonary disease
* p < 0.05 center 1 versus center 2
Characteristics All patients
N = 119
Center 1 (cisatracurium use)
N = 97
Center 2 (atracurium use)
N = 22
Age (years) 62 (52–73) 62 (51–72) 63 (52–73)
Male [n (%)] 78 (66) 61 (63) 17 (77)
Body mass index (kg/m2) 25.5 (23.4–29.6) 25.3 (23.1–29.6) 26.6 (23.7–32.2)
SAPS II (points) 51 (40–62) 50 (40–62) 51 (44–60)
SOFA (points) 9 (6–12) 9 (7–12) 9 (6–12)
Length of stay before ICU (days) 1 (0–4) 1 (0–4) 1 (0–3)
Main reason for ICU admission [n (%)]
 Medical 111 (93) 93 (96) 18 (82)*
 Surgical 8 (7) 4 (4) 4 (18)
Main reason for neuromuscular blockade [n (%)]
 ARDS 94 (79) 78 (80) 16 (73)*
 Exacerbations of COPD 7 (6) 5 (5) 2 (9)
 Status asthmaticus 3 (3) 3 (3) 0
 Other respiratory failures 6 (5) 5 (5) 1 (4.5)
 Abdominal compartment syndromes 5 (4) 2 (2) 3 (13.5)
 Miscellaneous 4 (3) 4 (4) 0
Main comorbidities [n (%)]
 Diabetes 16 (13) 14 (14) 2 (9)
 Renal disease 8 (7) 7 (7) 1 (5)
 Cirrhosis 16 (13) 14 (14) 2 (9)
 Corticosteroid treatment 12 (10) 11 (11) 1 (5)
Sepsis [n (%)] 85 (71) 68 (70) 17 (77)
Catecholamines [n (%)] 78 (66) 62 (64) 16 (73)






















p < 0.0001 p < 0.0001
p < 0.0001
n= 996 n= 996 n= 996






Fig. 2 Comparison of results obtained by the train of four and the 
clinical assessment of neuromuscular blockade recorded over the 
entire study period
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ICU‑acquired weakness 7 days after awakening the patient
The MRC score could be assessed in 47 patients who 
were able to follow commands 7  days after awaken-
ing. ICU-AW was diagnosed in 14 patients (30%). 
After comparisons between patients with and without 
ICU-AW, proportions of patients with liver cirrhosis [0 
(0%) vs. 5 (15%), respectively, p = 0.32], diabetes mel-
litus [1 (14%) vs. 2 (6%), respectively, p =  0.45], renal 
disease [0 (0%) vs. 3 (9%), respectively, p =  0.42] and 
who received concomitant administration of steroids 
during the ICU stay [9(64%) vs. 15 (33%), respectively, 
p = 0.23] did not differ significantly. The other risk fac-
tors for ICU-AW assessed in the study did not differ 
significantly between patients with and without ICU-
AW (Additional file  4: Table S4). Proportion of ulnar 
and facial TOF = 0 during treatment with NMBAs was 
significantly higher in patients with ICU-AW than in 
patient without ICU-AW, although it was not signifi-
cant for total doses and duration of cisatracurium and 
atracurium (Table 3).
Discussion
To our knowledge, here we report the largest prospective 
cohort of critically ill patients paralyzed with the recom-
mended doses of benzylisoquinoliniums and assessed for 
neuromuscular blockade by both a clinical evaluation 
and ulnar and facial TOF measurements. As expected 
we found that the evaluation of neuromuscular blockade 
differed vastly between the TOF and clinical assessment 
but also that TOF counts differed significantly between 
evaluation of facial and hand muscles. Furthermore, we 
found that the proportion of TOF  =  0 measurements 
was significantly higher in patients with ICU-AW than 
in patients with no ICU-AW. An important result is that 
findings did not differ whether patients received cisatra-
curium or atracurium.
As it is already known in the operating room setting 
[10, 11], our study shows that an overall clinical assess-
ment of the depth of a neuromuscular blockade is not 
correlated with the TOF count in critically ill patients. 














































Clinical assessments Facial TOF measurements
Over paralyzed (TOF= 0)
Well paralyzed (TOF= 1-2)
Under paralyzed (TOF= 3-4)
Ulnar TOF measurements
Over paralyzed (TOF= 0)
Well paralyzed (TOF= 1-2)
Under paralyzed (TOF= 3-4)
of mechanical venlaon
P value for trends
Over paralyzed, p= 0.33
Well paralyzed, p= 0.81
Under paralyzed, p= 0.67
P value for trends
Over paralyzed, p= 0.005
Well paralyzed, p= 0.99
Under paralyzed, p= 0.01
P value for trends
Over paralyzed, p= 0.07
Well paralyzed, p= 0.88
Under paralyzed, p <0,001
Fig. 3 Clinical, facial, and ulnar train‑of‑four (TOF) measurements recorded on the first 4 days of mechanical ventilation from the diagnosis of ARDS
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studies, where the clinical assessment was performed by 
nurses and not by physicians, and two of these studies 
took place in pediatric ICUs [15–17]. Our results high-
light the major discrepancy between clinical assessment 
and measures obtained after PNS but also between ulnar 
and facial TOF measurements.
A major finding of this study was that the objective of 
TOF count of 1 or 2 was obtained in only less than 10% 
of the measurements when patients are monitored only 
according to clinical assessment, even though the NMBA 
infusion rates were in accordance with the recommenda-
tions [2, 4]. Few studies supported the recommendations 
of monitoring the TOF in the ICU. Rudis et al. [8] com-
pared in one group of patients paralyzed with an ami-
nosteroid managed with a clinical assessment and one 
group managed with a TOF for an objective of 1/4. These 
authors observed a decreased amount of infused NMBAs 
and a faster recovery of muscle paralysis and spontane-
ous ventilation in the TOF group. However, in studies 
using benzylisoquinoliniums, there was no advantage 
for amount of infused NMBAs or residual weakness 
with a TOF compared to a clinical assessment [22, 28]. 
It is noteworthy that in the 2016 American recommen-
dations, the only indication for NMBAs is ARDS with a 
Table 2 PaO2/FiO2 ratios, plateau pressure, and calculated driving pressure recorded on the first 4 days of mechanical 
ventilation (MV) from the diagnosis of ARDS, distinguished according to results for facial train of four (TOF), and com-
pared day by day
IQR interquartile ranges
* No significant difference for the daily first and second measurements when compared between results obtained for facial TOF = 0, facial TOF = 1–2, and facial 
TOF = 3–4
Day of MV Day 0 Day 1 Day 2 Day 3
First Second First Second First Second First Second
Measurements (n) 80 38 88 65 66 37 51 36
PaO2/FiO2 (mmHg), median (IQR)*
 Facial TOF = 0 115 (82–154) 170 (100–209) 148 (116–231) 171 (143–192) 178 (128–212) 151 (105–196) 160 (118–201) 136 (114–183)
 Facial TOF = 1–2 111 (93–206) 160 (107–220) 203 (121–269) 142 (121–178) 198 (154–228) – 183 (146–213) 121 (113–130)
 Facial TOF =  3–4 98 (77–148) 168 (137–246) 159 (128–198) 195 (162–239) 185 (140–232) 220 (210–240) 187 (130–211) 154 (140–184)
Plateau pressure, cmH2O, median (IQR)*
 Facial TOF = 0 24 (19–26) 22 (20–25) 23 (19–25) 22 (20–24) 22 (20–24) 24 (20–25) 23 (20–25) 23 (22–26)
 Facial TOF = 1–2 27 (23–27) 23 (23–24) 21 (17–23) 21 (19–27) 20 (18–20) – 24 (21–26) 21 (17–25)
 Facial TOF =  3–4 22 (20–27) 21 (20–22) 22 (20–24) 22 (21–24) 22 (20–24) 22 (20–24) 22 (19–24) 23 (20–25)
Driving pressure, cmH2O, median (IQR)*
 Facial TOF = 0 11 (9.5–18) 11 (8.5–14) 11 (9–13) 10 (9–12) 11 (9–13) 12 (10–14) 12 (11–17) 13 (11–17)
 Facial TOF = 1–2 12 (12–14) 11 (10–12) 9 (9–11.5) 10 (8–15) 9.5 (8–11.5) – 11.5 (10–14) 10 (9–11)
 Facial TOF = 3–4 12 (10–16) 10.5 (8.5–12) 11 (10–14) 11 (9.5–13) 11 (9–13) 11 (8.5–12.5) 10 (9.5–13.5) 12 (9.5–15)
Table 3 Neuromuscular blockade, train-of-four (TOF) measurements, and  intensive care unit-acquired weakness (ICU-
AW) 7 days after awaking
Continuous variables are reported as medians and interquartile ranges (25th–75th percentiles)
ICU-AW intensive care unit-acquired weakness, NMBAs neuromuscular blocking agents, TOF train of four
ICU‑AW = Yes ICU‑AW = No p value
Whole population N = 14 N = 33
 Measures of facial TOF = 0/all measures of facial TOF 75/147 (51%) 97/243 (40%) 0.03
 Measures of ulnar TOF = 0/all measures of ulnar TOF 111/147 (76%) 151/243 (62%) 0.006
Center 1 N = 12 N = 29
 Cisatracurium total dose (mg) 1482 (635–3257) 998 (591–1470) 0.25
 Cisatracurium duration (h) 89 (42–210) 65 (35–110) 0.28
Center 2 N = 2 N = 4
 Atracurium total dose (mg) 1056 (1092–1320) 472 (418–749) 0.06
 Atracurium duration (h) 190 (186–195) 93 (76–105) 0.07
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ratio PaO2/FiO2 less than 150, and that no dosage and no 
objective of TOF are advocated [5].
A favorable impact of a neuromuscular blockade on 
the 90-day survival for severe ARDS patients was dem-
onstrated in a well-designed study [3] with higher doses 
than recommended (i.e., 37.5  mg/h of cisatracurium), 
without monitoring the TOF. These doses were based on 
two previous studies from the same group with a goal of 
zero twitch for everyone during 48 h [29, 30]. This favora-
ble effect of the NMBAs on ARDS may be due to an 
improvement in adjustment of tidal volume and plateau 
pressure with a reduction of asynchronies and ventilator-
induced lung injuries, to an improvement of oxygenation, 
and finally to an anti-inflammatory effect [3, 29–31]. In 
one study, an objective of a TOF at 0/4 was compared to 
an objective at 2/4 [32]. As in our study, the plateau pres-
sure and ratio PaO2/FiO2 did not differ between the TOF 
values. However, we did not assess asynchronies and we 
did not measure levels of cytokines, and thus, we cannot 
exclude that a deeper level of neuromuscular blockade is 
required to prevent lesions induced by bio-traumatism. 
Repeated measurements suggest also that higher than 
recommended and increasing doses of NMBAs dur-
ing the first days of MV are required to obtain no facial 
TOF response and consequently total paralysis of the dia-
phragmatic and accessory muscles [3, 29, 30].
The proportion of TOF 3 or 4 increased significantly 
with time while patients receive the recommended doses 
of NMBAs. This has already been attributed to an up-
regulation of acetylcholine receptors, although some 
authors did not find the same results [13, 22]. The phar-
macokinetics of NMBAs in critically ill patients can be 
affected by many conditions, such as sepsis and/or shock 
[12]. In addition, it has been shown that ICU patients are 
less sensitive to neuromuscular blockade than patients in 
the operating room [14].
The link between NMBAs and ICU-AW, especially 
with benzylisoquinoliniums, is debated [1, 25, 27, 33, 34]. 
We diagnosed ICU-AW in 30% of our patients able to 
perform the MRC score on day 7 after their awakening, 
which is in accordance with the literature [25, 27]. The 
percentages of the ulnar and facial TOF  =  0 measure-
ments were higher in the cases of ICU-AW, while total 
doses and duration of NMBAs were not associated with 
a higher risk of ICU-AW. Further studies are required to 
determine whether that aiming for an objective of TOF 
count of 1 or 2 rather than zero could reduce amounts 
of infused NMBAs, thus lowering the risk of ICU-AW. In 
addition, there are many risk factors for ICU-AW which 
could be confounders [25, 27] and the present study was 
underpowered to assess most of them.
The results showing that TOF = 0 is more frequent at 
the ulnar site is not surprising since the orbicularis oculi 
muscle is known to be less sensitive to NMBAs than the 
adductor pollicis muscle. We monitored the TOF on 
the facial and the ulnar nerves because the facial site is 
advised in the French recommendations, but not in the 
recommendations from the Society of Critical Care Med-
icine [2, 4]. The orbicularis oculi muscle better assesses 
the depth of relaxation of the diaphragm, which is often 
the goal of a neuromuscular blockade in the ICU, espe-
cially in cases of ARDS [29, 30]. Although our study was 
not designed to, it seems more appropriate to monitor 
the facial TOF in ARDS patients to provide the adequate 
dose of NMBAs, at least during the first 48 h of MV in 
order to totally paralyze the diaphragmatic muscle as 
suggested by Papazian et  al. [3]. Nevertheless, it is cur-
rently impossible to determine the aim of TOF to achieve 
in ARDS patients because in the only study [3] that 
shown a benefit in the use of NMBAs, no monitoring of 
TOF was done. Of note, the two centers did not use the 
same peripheral nerve stimulator and we believe that dif-
ferences in NMBAs and TOF monitors between centers 
increase the external validity of the study.
Our study has some limitations. We included mainly 
medical patients so our results may not be generalized 
to all ICUs. We did not use an automated TOF measure-
ment. More measurements would have provided a more 
accurate assessment, although the best frequency for 
measurement is not specified in the literature [1, 2, 4]. 
Ideally, the intensity of the stimulating current has to be 
tested for each patient before an NMBA infusion, which 
is difficult in real practice. Thus, we chose an intensity of 
the stimulating current of 50 mA for all patients, which 
was in agreement with some authors [20, 21]. Although 
we restrained ourselves to follow the advice published 
in the literature, the measurement of the TOF can be 
impaired by technical pitfalls such as incorrect position-
ing of electrodes [20, 21, 35]. The clinical evaluation of a 
neuromuscular blockade by physicians was not recorded 
in a standardized form, and we did not find models in the 
literature. The depth of sedation may have influenced the 
clinical evaluation of the neuromuscular blockade. Asyn-
chronies and spontaneous breathing efforts were not pre-
cisely and extensively recorded in ARDS patients. Finally, 
we did not assess results of TOF on extubation times 
mainly because weaning process differed slightly between 
the two centers.
In conclusion, our study shows that there is a huge dis-
crepancy between the clinical assessment and the TOF 
measurements in critically ill patients, that TOF count of 
1 or 2 is a goal rarely achieved at usual doses of NMBAs, 
but also that respiratory objectives for plateau pressure 
and oxygenation can be obtained in ARDS patients with-
out TOF monitoring. Our results do not suggest that the 
need for monitoring NMBAs could itself be questioned 
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but rather that site for nerve stimulation and objective for 
TOF count could differ according to critically ill patients, 
reasons for neuromuscular blockade, and courses of the 
diseases. Nevertheless, more studies are needed to estab-
lish the best target of the TOF count to provide necessary 
and sufficient muscle relaxation and avoid residual muscu-
lar weakness.
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